prophase labs is a diversified natural health medical science company. for more information visit us at www.prophaselabs.com.
Company profile
Ticker
PRPH
Exchange
Website
CEO
Ted William Karkus
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
Former names
QUIGLEY CORP
SEC CIK
Corporate docs
Subsidiaries
Nebula Genomics, Inc. • Pharmaloz Manufacturing Inc. • ProPhase Digital Media, Inc. • ProPhase Biopharma, Inc. • ProPhase Diagnostics, Inc. • ProPhase Diagnostics NJ, Inc. • ProPhase Diagnostics NY, Inc. • Quigley Pharma Inc. • TK Supplements, Inc. • ProPhase Precision Medicine, Inc. ...
IRS number
232577138
PRPH stock data
Latest filings (excl ownership)
8-K
Entry into a Material Definitive Agreement
18 Apr 24
NT 10-K
Notice of late annual filing
18 Mar 24
8-K
Nebula Genomics secures major international B2B deal – Additional significant B2B deals in final stages
15 Mar 24
8-K
ProPhase poised to ramp up growth at Pharmaloz and Nebula Genomics in 2024
4 Jan 24
10-Q
2023 Q3
Quarterly report
13 Nov 23
8-K
ProPhase Labs Announces Financial Results
9 Nov 23
10-Q
2023 Q2
Quarterly report
11 Aug 23
8-K
ProPhase Labs Announces Financial Results
10 Aug 23
8-K
Navidea Biopharmaceuticals Rejects ProPhase Labs Offer To Acquire Certain Assets of Navidea
29 Jun 23
8-K
Regulation FD Disclosure
22 Jun 23
Transcripts
PRPH
Earnings call transcript
2023 Q3
9 Nov 23
PRPH
Earnings call transcript
2023 Q2
10 Aug 23
PRPH
Earnings call transcript
2023 Q1
11 May 23
PRPH
Earnings call transcript
2022 Q4
28 Mar 23
PRPH
Earnings call transcript
2022 Q3
10 Nov 22
PRPH
Earnings call transcript
2022 Q2
12 Aug 22
PRPH
Earnings call transcript
2022 Q1
13 May 22
PRPH
Earnings call transcript
2021 Q4
30 Mar 22
PRPH
Earnings call transcript
2021 Q3
12 Nov 21
PRPH
Earnings call transcript
2021 Q2
14 Aug 21
Latest ownership filings
4/A
Ted William Karkus
21 Mar 24
4
Jed Latkin
19 Mar 24
3
Jed Latkin
19 Mar 24
4
Warren Hirsch
19 Mar 24
4
LOUIS MD GLECKEL
19 Mar 24
4
Jason Michael Barr
19 Mar 24
4
Ted William Karkus
19 Mar 24
SC 13D/A
Karkus Ted William
19 Mar 24
SC 13G/A
Lantern Pharma Inc.
14 Feb 24
4/A
Warren Hirsch
22 Jun 23
Financial summary
Quarter (USD) | Sep 23 | Jun 23 | Mar 23 | Dec 22 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Annual (USD) | Dec 22 | Dec 21 | Dec 20 | Dec 19 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Cash burn rate (est.) | Burn method: Change in cash | Burn method: Operating income | Burn method: FCF (opex + capex) | Last Q | Avg 4Q | Last Q | Avg 4Q | Last Q | Avg 4Q |
---|---|---|---|---|---|---|
Cash on hand (at last report) | 702.00 k | 702.00 k | 702.00 k | 702.00 k | 702.00 k | 702.00 k |
Cash burn (monthly) | 1.04 mm | 1.84 mm | 2.26 mm | 1.33 mm | 1.55 mm | 860.33 k |
Cash used (since last report) | 7.09 mm | 12.54 mm | 15.40 mm | 9.09 mm | 10.56 mm | 5.86 mm |
Cash remaining | -6.38 mm | -11.84 mm | -14.70 mm | -8.38 mm | -9.86 mm | -5.16 mm |
Runway (months of cash) | -6.1 | -6.4 | -6.5 | -6.3 | -6.4 | -6.0 |
Institutional ownership, Q2 2023
12.1% owned by funds/institutions
13F holders | Current |
---|---|
Total holders | 45 |
Opened positions | 11 |
Closed positions | 5 |
Increased positions | 10 |
Reduced positions | 15 |
13F shares | Current |
---|---|
Total value | 13.29 bn |
Total shares | 2.18 mm |
Total puts | 79.60 k |
Total calls | 14.30 k |
Total put/call ratio | 5.6 |
Largest owners | Shares | Value |
---|---|---|
Vanguard | 601.84 k | $4.37 bn |
Renaissance Technologies | 300.51 k | $2.18 mm |
STA Wealth Management | 156.02 k | $1.13 bn |
Geode Capital Management | 133.14 k | $966.56 mm |
Perritt Capital Management | 97.30 k | $706.40 mm |
AMP Ameriprise Financial | 92.73 k | $673.21 mm |
BLK Blackrock | 85.57 k | $621.25 mm |
American Century Companies | 74.57 k | $541.36 mm |
BK Bank Of New York Mellon | 62.47 k | $453.55 mm |
O'shaughnessy Asset Management | 58.56 k | $425.14 mm |
Recent insider trades
Date | Owner | Security | Transaction | Code | Indirect | 10b5-1 | $Price | #Shares | $Value | #Remaining |
---|---|---|---|---|---|---|---|---|---|---|
17 Mar 24 | Gleckel Louis MD | Option Common Stock | Grant | Acquire A | No | No | 6 | 70,000 | 420.00 k | 70,000 |
17 Mar 24 | Barr Jason Michael | Option Common Stock | Grant | Acquire A | No | No | 6 | 70,000 | 420.00 k | 70,000 |
17 Mar 24 | Warren Hirsch | Option Common Stock | Grant | Acquire A | No | No | 6 | 70,000 | 420.00 k | 70,000 |
17 Mar 24 | Karkus Ted William | Option Common Stock | Grant | Acquire A | No | No | 6 | 400,000 | 2.40 mm | 400,000 |
News
ProPhase Labs Unveils Project ZenQ-AI; Leveraging ProPhase Labs' AI Platform, Massive Genomics Database And Patented Esophageal Cancer Insights For Antibody Drug Conjugates Development
16 Apr 24
ProPhase Labs Seeks To Transform Esophageal Cancer Detection And Management With Launch Of Its BE-Smart Test In H2 2024
10 Apr 24
ProPhase Labs Q4 EPS $(0.51) Misses $(0.26) Estimate, Sales $4.35M Miss $10.69M Estimate
15 Mar 24
Earnings Scheduled For March 15, 2024
15 Mar 24
ProPhase Labs's Earnings: A Preview
14 Mar 24
Press releases
ProPhase Labs Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
1 Apr 24
PROPHASE LABS TO PRESENT 2023 YEAR END FINANCIAL RESULTS ON MARCH 15, 2024
8 Mar 24
Diamond Equity Research Releases Update Note on ProPhase Labs Inc. (NASDAQ: PRPH)
21 Feb 24
Sidus Space Appoints Bill White as Chief Financial Officer
8 Feb 24
Diamond Equity Research Releases In Depth Update Note on ProPhase Labs, Inc. (NASDAQ: PRPH) subsidiary, Pharmaloz Manufacturing, Inc. (PMI)
8 Feb 24